Key Partnerships

Osiris Therapeutics, Inc. has enered into an agreement with Genzyme Corporation for the development and commercialization of Prochymal and Chondrogen. Under the terms of the agreement, Osiris will commercialize Prochymal in the United States and Canada, and Genzyme will commercialize the treatment in all other countries. 

Osiris also has a partnership with Genzyme to develop Prochymal as a medical countermeasure to nuclear terrorism and other radiological emergencies. The agreement provides for Genzyme to receive a royalty on sales of Prochymal, limited to those sales made under contract to U.S. or Allied Governmental Agencies for Emergency Preparedness.

Osiris joined JCR Pharmaceutical Corporation to produce and market Prochymal for GvHD in Japan.